Background: Human CD4 + and CD8 + stem cell memory T cells (TSCM) represent a minor fraction of circulating lymphocytes characterized by stemness and long-term in vivo persistence. CD4 + TSCM are preferentially infected and constitute a reservoir for HIV-1, whereas CD8 + TSCM appear to play a protective role. However, little is known about CD4 + and CD8 + TSCM in the only other human pathogenic retroviral infection, human T-cell leukemia virus type 1 (HTLV-1). HTLV-1 is the etiological agent of both Adult T-cell Leukemia (ATL) and HTLV-1 associated myelopathy/tropical spastic paraperesis (HAM/TSP), a neuroinflammatory disorder. In ATL, CD4 + TSCM cells were identified as the hierarchical leukemic stem cell, but data in HAM/TSP are lacking. Age is a major risk factor for both ATL and HAM/TSP, as both diseases generally manifest several decades after infection. Therefore, we explored a possible link between TSCM, age and disease status in human retroviral infections in a cross-sectional study, using multiparametric flow cytometry.
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Results:
We found that CD4 + or CD8 + TSCM levels (quantified as CD3 + CD45RA + CD45RO -CD27 + CCR7 + Fas hi ) do not differ between healthy controls and untreated HTLV-1 infected individuals with and without neuroinflammatory disorder. However, we found both TSCM as well as CD8 + TSCM significantly accumulated with age, resulting in a >400% increase in elderly HTLV-1 infected individuals (>60 years). A significant correlation between age and TSCM signature genes was validated at the transcriptome level in an independent cohort. CD8 + but not CD4 + TSCM were significantly decreased in untreated HIV-1 infection. Unexpectedly, CD8 + TSCM recovery upon successful antiretroviral treatment was essentially complete (92.2±11.0%) in younger (<45 years) individuals, but significantly lower (37.3±6.1%) in older (>45 years) individuals (p=0.0003).
Conclusion:
In HTLV-1 infection, an age-dependent accumulation of CD4 + and CD8 + TSCM points towards a possible protective role of CD8 TSCM in the elderly against leukemic but not neuroinflammatory disease. HIV-1-infected individuals lose their ability to restore CD8 + TSCM levels upon successful antiretroviral therapy at later age (>45 years), which might eventually lead to immunological failure and decreased vaccine efficacy.
BRIEF REPORT

Introduction
Human CD4 + and CD8 + stem cell memory T cells (TSCM) represent a small fraction (2-3%) of circulating lymphocytes characterized by intrinsic apoptosis resistance, proliferation and long-term in vivo persistence (Gattinoni et al., 2011) . CD4 + TSCM are preferentially infected and constitute a long-lived cellular reservoir for human immunodeficiency virus-1 (HIV-1) (Buzon et al., 2014) , whereas CD8 + TSCM appear to play a protective role (Ribeiro et al., 2014; Vigano et al., 2015) . However, little is known about CD4 + and CD8 + TSCM in the only other human pathogenic retroviral infection, namely human T-cell leukemia virus type 1(HTLV-1).
HTLV-1 is the etiological agent of both Adult T-cell Leukemia (ATL) and HTLV-1 associated myelopathy/tropical spastic paraperesis (HAM/TSP), a neuroinflammatory disorder. Age is a major risk factor for both ATL and HAM/TSP, as both diseases generally manifest several decades after infection. In ATL, CD4 + TSCM cells were identified as the hierarchical leukemic stem cell (Nagai et al., 2015) . In HAM/TSP, we recently documented a predominant Fas hi phenotype linked to lymphoproliferation and inflammation (Menezes et al., 2017) , but its possible link to CD4 + and CD8 + TSCM subsets is unknown. Interestingly, FAS polymorphisms determine both ATL susceptibility (Farre et al., 2008) and CD4 + and CD8 + Tscm levels in a large twin study (Roederer et al., 2015) . Pulko et al. recently identified a novel human memory T cell subset with a naïve phenotype, accumulating with age (Pulko et al., 2016) .
While Pulko et al. elaborately explored various CD8 + naïve and memory cellular subsets and elegantly described a CD45RA + IFN- + CXCR3 + Fas lo subset of memory T cells with a naïve phenotype (TMNP) and responsiveness to chronic but not acute viral infections, their study did not include T memory stem cells (TSCM) (Pulko et al., 2016) . Therefore, we explored a possible link between TSCM, age and disease status in human retroviral infections in a crosssectional study.
Results and Discussion
We found that CD4 + or CD8 + TSCM levels (quantified as CD3 + CD45RA + CD45RO -CD27 + CCR7 + Fas hi ) do not differ between healthy controls (HC, seronegative for HIV-1 and HTLV-1) and untreated HTLV-1 infected individuals with and without neuroinflammatory disorder (AC and HAM/TSP patients, Fig. 1A ). Whereas the hallmark of HIV-1 infection is CD4 + depletion, HTLV-1 infection propels CD4 + cells into the cell cycle while protecting CD8 + cells from apoptosis (Sibon et al., 2006) . However, CD4 + TSCM abundance was not significantly different between HC, untreated HTLV-1 (HIV-1 negative), untreated HIV-1 and treated HIV-1 infection (successful antiretroviral therapy with undetectable viral load), as shown in Fig. 1B . Nevertheless, CD8 + TSCM was significantly decreased in untreated HIV-1 infection compared to all other groups (Fig. 1C) . In parallel to HTLV-1 infection, CD4 + and CD8 + TSCM levels (%) did not differ in untreated HIV-1-infected individuals with different degrees of disease progression, i.e. controllers, non-controllers and immunological progressors (Ribeiro et al., 2014) .
In a large cohort of healthy controls (n=460), CD4 + TSCM were found to modestly increase by 25% over a 30-year period in HC (p=0.06, Roederer et al. unpublished), whereas CD8 + TSCM levels decrease 25% over the same period (p=0.004, Roederer et al., unpublished).
Unexpectedly, in untreated HTLV-1-infected individuals, both CD4 + TSCM as well as CD8 + TSCM significantly accumulated with age (r=0.60, p=0.016 and r=0.73, p=0.0019, respectively), resulting in a >400% increase in the elderly (>60 years Fig. 2A ). This effect was not due to differences in viral factors, as CD4 + and CD8 + TSCM levels did not correlate to proviral load nor viral mRNAs (Tax and HBZ). Furthermore, age-dependent accumulation was observed in the combined HTLV-1-infected group, as well as in the asymptomatic and HAM/TSP subgroups, implying that age, but not disease status, determines CD4 + TSCM and CD8 + TSCM levels in HTLV-1 infection. 
HTLV-1 asymptomatic carriers (AC) and HAM/TSP patients, while CD8 + TSCM cells are depleted in untreated HIV-1-infected individuals. (A) No significant difference in the levels of CD4 + and CD8 + TSCM cells (CD3 + CD45RA + CD45RO -CD27 + CCR7 + Fas hi ) quantified by flow cytometry in HC (n=7 CD4 + TSCM, n=9 CD8 + TSCM), AC (n=6) and HAM/TSP patients (n=9). (B) No significant difference in the levels of CD4 + TSCM between HC (n=19), untreated HTLV-1-(n=13), untreated HIV-1-(n=77) and treated (n=27) HIV-1-infected individuals. (C) CD8 + TSCM levels are decreased in untreated HIV-1-infected individuals when compared to HC, untreated HTLV-1 and treated HIV-1 infected individuals. (***p < 0.001; Kruskal-Wallis test with Dunn's post-test).
We validated these findings at the transcriptome level using an independent, previously published cohort (Tattermusch et al., 2012) . Transcript levels of TSCM signature markers 
TMNP-Memory and Naïve, in HTLV-1 infected individuals from an independent published UK cohort (n=30).
In contrast to HTLV-1-infected individuals, we observed a significant age-dependent decline of CD8 + TSCM (p=0.0017, r=-0.57) but not CD4 + TSCM levels in treated HIV-1 patients (Fig. 3A) .
There was no correlation of CD4 + TSCM or CD8 + TSCM with age in untreated HIV-1 patients (Fig.   3B ), again independent of disease status (data not shown). When calculating the percentage of CD8 + TSCM depletion (relative to HC), CD8 + TSCM depletion was strikingly similar between younger (<45 years) and older (>45 years) untreated HIV-1-infected individuals ( Figure 3C ).
However, the percentage of CD8 + TSCM recovery upon successful treatment was essentially complete (92.2±11.0%) in younger (<45 years) individuals, but significantly lower (37.3±6.1%) in older (>45 years) individuals (p=0.0003, Figure 3D ), which parallels HIVassociated CD8 + senescence in this age group (Cobos Jimenez et al., 2016) . Thus, contrary to HTLV-1 infection, disruption of CD8 + TSCM homeostasis occurs at an early age in HIV-1 infection, but is relatively stable over the age groups (defective CD8 TSCM recovery is apparent at different cut-offs, i.e. in age groups >40, >50 and >60 years, data not shown). 
